INR 750.9
(-0.05%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 783.82 Million INR | 9.9% |
2022 | 713.21 Million INR | -15.84% |
2021 | 847.44 Million INR | 44.35% |
2020 | 587.06 Million INR | 27.85% |
2019 | 459.19 Million INR | 9.65% |
2018 | 418.77 Million INR | 12.22% |
2017 | 373.16 Million INR | 2.97% |
2016 | 362.39 Million INR | 14.33% |
2015 | 316.97 Million INR | 9.49% |
2014 | 289.51 Million INR | -6.7% |
2013 | 310.3 Million INR | -25.93% |
2012 | 418.9 Million INR | -10.92% |
2011 | 470.24 Million INR | -15.42% |
2010 | 555.94 Million INR | 155.19% |
2009 | 217.85 Million INR | 25.39% |
2008 | 173.74 Million INR | -21.45% |
2007 | 221.18 Million INR | 22.81% |
2006 | 180.1 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q3 | - INR | -100.0% |
2023 Q4 | 783.82 Million INR | 0.0% |
2023 FY | 783.82 Million INR | 9.9% |
2023 Q1 | - INR | -100.0% |
2023 Q2 | 930.51 Million INR | 0.0% |
2022 Q4 | 713.21 Million INR | 0.0% |
2022 FY | 713.21 Million INR | -15.84% |
2022 Q1 | - INR | -100.0% |
2022 Q2 | 957.25 Million INR | 0.0% |
2022 Q3 | - INR | -100.0% |
2021 Q4 | 847.44 Million INR | 0.0% |
2021 Q2 | 718.95 Million INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2021 FY | 847.44 Million INR | 44.35% |
2021 Q1 | - INR | -100.0% |
2020 Q3 | - INR | -100.0% |
2020 Q4 | 587.06 Million INR | 0.0% |
2020 FY | 587.06 Million INR | 27.85% |
2020 Q1 | - INR | -100.0% |
2020 Q2 | 557.49 Million INR | 0.0% |
2019 Q3 | - INR | -100.0% |
2019 Q2 | 496.65 Million INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2019 Q4 | 459.19 Million INR | 0.0% |
2019 FY | 459.19 Million INR | 9.65% |
2018 Q1 | - INR | -100.0% |
2018 FY | 418.77 Million INR | 12.22% |
2018 Q4 | 418.77 Million INR | 0.0% |
2018 Q3 | - INR | -100.0% |
2018 Q2 | 352.45 Million INR | 0.0% |
2017 FY | 373.16 Million INR | 2.97% |
2017 Q2 | 368.72 Million INR | 0.0% |
2017 Q4 | 373.16 Million INR | 0.0% |
2017 Q1 | - INR | -100.0% |
2016 FY | 362.39 Million INR | 14.33% |
2016 Q4 | 362.39 Million INR | 0.0% |
2015 FY | 316.97 Million INR | 9.49% |
2014 FY | 289.51 Million INR | -6.7% |
2013 FY | 310.3 Million INR | -25.93% |
2012 FY | 418.9 Million INR | -10.92% |
2012 Q2 | 834.45 Million INR | 0.0% |
2012 Q4 | 418.9 Million INR | 0.0% |
2011 FY | 470.24 Million INR | -15.42% |
2010 FY | 555.94 Million INR | 155.19% |
2009 FY | 217.85 Million INR | 25.39% |
2008 FY | 173.74 Million INR | -21.45% |
2007 FY | 221.18 Million INR | 22.81% |
2006 FY | 180.1 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Sigachi Industries Limited | 2.53 Billion INR | 69.034% |
Ind-Swift Limited | 13.45 Billion INR | 94.174% |
Bajaj HealthCare Limited | 4.86 Billion INR | 83.897% |
Sakar Healthcare Limited | 1.26 Billion INR | 37.953% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.485% |
Innova Captab Limited | 4.89 Billion INR | 84.003% |
Divi's Laboratories Limited | 18.99 Billion INR | 95.872% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 78.591% |
Morepen Laboratories Limited | 4.45 Billion INR | 82.425% |
Mankind Pharma Limited | 23.87 Billion INR | 96.717% |
Sequent Scientific Limited | 8.27 Billion INR | 90.527% |
Wanbury Limited | 3.15 Billion INR | 75.16% |
Laurus Labs Limited | 42.71 Billion INR | 98.165% |
Nectar Lifesciences Limited | 11.21 Billion INR | 93.013% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 84.871% |
Alembic Limited | 1.43 Billion INR | 45.268% |
Hikal Limited | 12.99 Billion INR | 93.968% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 95.184% |
Neuland Laboratories Limited | 5.49 Billion INR | 85.745% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 92.68% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 98.796% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 87.615% |
Themis Medicare Limited | 1.88 Billion INR | 58.473% |
RPG Life Sciences Limited | 1.38 Billion INR | 43.209% |
Zydus Lifesciences Limited | 71.79 Billion INR | 98.908% |
Lupin Limited | 96.23 Billion INR | 99.186% |
Wockhardt Limited | 39.87 Billion INR | 98.034% |
Vaishali Pharma Limited | 371.16 Million INR | -111.181% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 90.5% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -164.127% |
Jubilant Pharmova Limited | 61.27 Billion INR | 98.721% |
FDC Limited | 3.7 Billion INR | 78.868% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.267% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -21.734% |
Eris Lifesciences Limited | 38.26 Billion INR | 97.952% |
Venus Remedies Limited | 1.39 Billion INR | 43.723% |
ZIM Laboratories Limited | 2.08 Billion INR | 62.33% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 62.832% |
Par Drugs and Chemicals Limited | 159.79 Million INR | -390.531% |
Caplin Point Laboratories Limited | 3.5 Billion INR | 77.641% |
Shilpa Medicare Limited | 12.93 Billion INR | 93.939% |
Albert David Limited | 1.15 Billion INR | 31.848% |
Ajanta Pharma Limited | 10.71 Billion INR | 92.682% |
Hester Biosciences Limited | 3.59 Billion INR | 78.195% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 61.468% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | 94.438% |
Gufic Biosciences Limited | 5.59 Billion INR | 86.003% |
Windlas Biotech Limited | 1.76 Billion INR | 55.533% |
Procter & Gamble Health Limited | 2.56 Billion INR | 69.396% |
Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 54.487% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 60.339% |
Granules India Limited | 22.95 Billion INR | 96.585% |
Aarti Drugs Limited | 11.5 Billion INR | 93.187% |
Bal Pharma Limited | 2.51 Billion INR | 68.788% |
Alkem Laboratories Limited | 48.6 Billion INR | 98.387% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.573% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 27.055% |
Medicamen Biotech Limited | 940.36 Million INR | 16.647% |
Unichem Laboratories Limited | 8.06 Billion INR | 90.286% |
Bafna Pharmaceuticals Limited | 652.27 Million INR | -20.167% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -171.408% |
Valiant Laboratories Limited | 1.05 Billion INR | 25.933% |
Orchid Pharma Limited | 3.84 Billion INR | 79.61% |
Medico Remedies Limited | 438.24 Million INR | -78.856% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 65.764% |
Ipca Laboratories Limited | 33.74 Billion INR | 97.677% |
Brooks Laboratories Limited | 248.6 Million INR | -215.294% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 32.731% |
Piramal Enterprises Limited | 560.47 Billion INR | 99.86% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 99.045% |
NATCO Pharma Limited | 10.53 Billion INR | 92.558% |
Suven Life Sciences Limited | 148.62 Million INR | -427.398% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 73.643% |
Strides Pharma Science Limited | 37.68 Billion INR | 97.92% |
Indoco Remedies Limited | 10.34 Billion INR | 92.421% |
Alpa Laboratories Limited | 307.12 Million INR | -155.216% |
Lasa Supergenerics Limited | 541.92 Million INR | -44.637% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 79.865% |